Cargando…
Neuromyelitis Optica Spectrum Disorder With Anti-Aquaporin-4 Antibody: Outcome Prediction Models
BACKGROUND: Recognizing the predictors of disease relapses in patients with anti-aquaporin-4 antibody (AQP4-ab)-positive neuromyelitis optica spectrum disorder (NMOSD) is essential for individualized treatment strategy. We aimed to identify the factors that predicted relapses among patients with AQP...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012141/ https://www.ncbi.nlm.nih.gov/pubmed/35432315 http://dx.doi.org/10.3389/fimmu.2022.873576 |
_version_ | 1784687739098103808 |
---|---|
author | Wang, Liang Du, Lei Li, Qinying Li, Fang Wang, Bei Zhao, Yuanqi Meng, Qiang Li, Wenyu Pan, Juyuan Xia, Junhui Wu, Shitao Yang, Jie Li, Heng Ma, Jianhua ZhangBao, Jingzi Huang, Wenjuan Chang, Xuechun Tan, Hongmei Yu, Jian Zhou, Lei Lu, Chuanzhen Wang, Min Dong, Qiang Lu, Jiahong Zhao, Chongbo Quan, Chao |
author_facet | Wang, Liang Du, Lei Li, Qinying Li, Fang Wang, Bei Zhao, Yuanqi Meng, Qiang Li, Wenyu Pan, Juyuan Xia, Junhui Wu, Shitao Yang, Jie Li, Heng Ma, Jianhua ZhangBao, Jingzi Huang, Wenjuan Chang, Xuechun Tan, Hongmei Yu, Jian Zhou, Lei Lu, Chuanzhen Wang, Min Dong, Qiang Lu, Jiahong Zhao, Chongbo Quan, Chao |
author_sort | Wang, Liang |
collection | PubMed |
description | BACKGROUND: Recognizing the predictors of disease relapses in patients with anti-aquaporin-4 antibody (AQP4-ab)-positive neuromyelitis optica spectrum disorder (NMOSD) is essential for individualized treatment strategy. We aimed to identify the factors that predicted relapses among patients with AQP4-ab-positive NMOSD, develop outcome prediction models, and validate them in a multicenter validation cohort. METHODS: Between January 2015 and December 2020, 820 patients with NMOSD were registered at Huashan Hospital. We retrospectively reviewed their medical records, and included 358 AQP4-ab-positive patients with 1135 treatment episodes. Univariate and multivariate analyses were used to explore the predictors of relapse, severe visual or motor disability during follow-up. A model predicting the 1- and 2-year relapse-free probability was developed and validated in an external validation cohort of 92 patients with 213 treatment episodes. RESULTS: Lower serum AQP4-ab titer (< 1:100), higher Expanded Disability Status Scale (EDSS) score at onset (≥ 2.5), and use of intravenous methylprednisolone (IVMP) at the first attack predicted an overall lower annualized relapse rate. Older age (> 48 years), optic neuritis at onset, and higher onset EDSS score (≥ 2.5) significantly increased the risk for blindness, while IVMP at the first attack and maintenance therapy reduced the risk for blindness. Myelitis at onset increased the possibility of motor disability (EDSS ≥ 6.0), severe motor disability or death (EDSS ≥ 8.0), while maintenance therapy reduced these possibilities. Anderson and Gill model identified that the risk factors predicting recurrent relapses under certain treatment status were female gender, high AQP4-ab titer (≥ 1:100), previous attack under same therapy, lower EDSS score at treatment initiation (< 2.5), and no maintenance therapy or oral prednisone lasting less than 6 months. A nomogram using the above factors showed good discrimination and calibration abilities. The concordance indexes in the primary and validation cohort were 0.66 and 0.65, respectively. CONCLUSION: This study reports the demographic, clinical and therapeutic predictors of relapse, and severe visual or motor disability in NMOSD. Early identification of patients at risk of unfavorable outcomes is of paramount importance to inform treatment decisions. |
format | Online Article Text |
id | pubmed-9012141 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90121412022-04-16 Neuromyelitis Optica Spectrum Disorder With Anti-Aquaporin-4 Antibody: Outcome Prediction Models Wang, Liang Du, Lei Li, Qinying Li, Fang Wang, Bei Zhao, Yuanqi Meng, Qiang Li, Wenyu Pan, Juyuan Xia, Junhui Wu, Shitao Yang, Jie Li, Heng Ma, Jianhua ZhangBao, Jingzi Huang, Wenjuan Chang, Xuechun Tan, Hongmei Yu, Jian Zhou, Lei Lu, Chuanzhen Wang, Min Dong, Qiang Lu, Jiahong Zhao, Chongbo Quan, Chao Front Immunol Immunology BACKGROUND: Recognizing the predictors of disease relapses in patients with anti-aquaporin-4 antibody (AQP4-ab)-positive neuromyelitis optica spectrum disorder (NMOSD) is essential for individualized treatment strategy. We aimed to identify the factors that predicted relapses among patients with AQP4-ab-positive NMOSD, develop outcome prediction models, and validate them in a multicenter validation cohort. METHODS: Between January 2015 and December 2020, 820 patients with NMOSD were registered at Huashan Hospital. We retrospectively reviewed their medical records, and included 358 AQP4-ab-positive patients with 1135 treatment episodes. Univariate and multivariate analyses were used to explore the predictors of relapse, severe visual or motor disability during follow-up. A model predicting the 1- and 2-year relapse-free probability was developed and validated in an external validation cohort of 92 patients with 213 treatment episodes. RESULTS: Lower serum AQP4-ab titer (< 1:100), higher Expanded Disability Status Scale (EDSS) score at onset (≥ 2.5), and use of intravenous methylprednisolone (IVMP) at the first attack predicted an overall lower annualized relapse rate. Older age (> 48 years), optic neuritis at onset, and higher onset EDSS score (≥ 2.5) significantly increased the risk for blindness, while IVMP at the first attack and maintenance therapy reduced the risk for blindness. Myelitis at onset increased the possibility of motor disability (EDSS ≥ 6.0), severe motor disability or death (EDSS ≥ 8.0), while maintenance therapy reduced these possibilities. Anderson and Gill model identified that the risk factors predicting recurrent relapses under certain treatment status were female gender, high AQP4-ab titer (≥ 1:100), previous attack under same therapy, lower EDSS score at treatment initiation (< 2.5), and no maintenance therapy or oral prednisone lasting less than 6 months. A nomogram using the above factors showed good discrimination and calibration abilities. The concordance indexes in the primary and validation cohort were 0.66 and 0.65, respectively. CONCLUSION: This study reports the demographic, clinical and therapeutic predictors of relapse, and severe visual or motor disability in NMOSD. Early identification of patients at risk of unfavorable outcomes is of paramount importance to inform treatment decisions. Frontiers Media S.A. 2022-03-31 /pmc/articles/PMC9012141/ /pubmed/35432315 http://dx.doi.org/10.3389/fimmu.2022.873576 Text en Copyright © 2022 Wang, Du, Li, Li, Wang, Zhao, Meng, Li, Pan, Xia, Wu, Yang, Li, Ma, ZhangBao, Huang, Chang, Tan, Yu, Zhou, Lu, Wang, Dong, Lu, Zhao and Quan https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Wang, Liang Du, Lei Li, Qinying Li, Fang Wang, Bei Zhao, Yuanqi Meng, Qiang Li, Wenyu Pan, Juyuan Xia, Junhui Wu, Shitao Yang, Jie Li, Heng Ma, Jianhua ZhangBao, Jingzi Huang, Wenjuan Chang, Xuechun Tan, Hongmei Yu, Jian Zhou, Lei Lu, Chuanzhen Wang, Min Dong, Qiang Lu, Jiahong Zhao, Chongbo Quan, Chao Neuromyelitis Optica Spectrum Disorder With Anti-Aquaporin-4 Antibody: Outcome Prediction Models |
title | Neuromyelitis Optica Spectrum Disorder With Anti-Aquaporin-4 Antibody: Outcome Prediction Models |
title_full | Neuromyelitis Optica Spectrum Disorder With Anti-Aquaporin-4 Antibody: Outcome Prediction Models |
title_fullStr | Neuromyelitis Optica Spectrum Disorder With Anti-Aquaporin-4 Antibody: Outcome Prediction Models |
title_full_unstemmed | Neuromyelitis Optica Spectrum Disorder With Anti-Aquaporin-4 Antibody: Outcome Prediction Models |
title_short | Neuromyelitis Optica Spectrum Disorder With Anti-Aquaporin-4 Antibody: Outcome Prediction Models |
title_sort | neuromyelitis optica spectrum disorder with anti-aquaporin-4 antibody: outcome prediction models |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012141/ https://www.ncbi.nlm.nih.gov/pubmed/35432315 http://dx.doi.org/10.3389/fimmu.2022.873576 |
work_keys_str_mv | AT wangliang neuromyelitisopticaspectrumdisorderwithantiaquaporin4antibodyoutcomepredictionmodels AT dulei neuromyelitisopticaspectrumdisorderwithantiaquaporin4antibodyoutcomepredictionmodels AT liqinying neuromyelitisopticaspectrumdisorderwithantiaquaporin4antibodyoutcomepredictionmodels AT lifang neuromyelitisopticaspectrumdisorderwithantiaquaporin4antibodyoutcomepredictionmodels AT wangbei neuromyelitisopticaspectrumdisorderwithantiaquaporin4antibodyoutcomepredictionmodels AT zhaoyuanqi neuromyelitisopticaspectrumdisorderwithantiaquaporin4antibodyoutcomepredictionmodels AT mengqiang neuromyelitisopticaspectrumdisorderwithantiaquaporin4antibodyoutcomepredictionmodels AT liwenyu neuromyelitisopticaspectrumdisorderwithantiaquaporin4antibodyoutcomepredictionmodels AT panjuyuan neuromyelitisopticaspectrumdisorderwithantiaquaporin4antibodyoutcomepredictionmodels AT xiajunhui neuromyelitisopticaspectrumdisorderwithantiaquaporin4antibodyoutcomepredictionmodels AT wushitao neuromyelitisopticaspectrumdisorderwithantiaquaporin4antibodyoutcomepredictionmodels AT yangjie neuromyelitisopticaspectrumdisorderwithantiaquaporin4antibodyoutcomepredictionmodels AT liheng neuromyelitisopticaspectrumdisorderwithantiaquaporin4antibodyoutcomepredictionmodels AT majianhua neuromyelitisopticaspectrumdisorderwithantiaquaporin4antibodyoutcomepredictionmodels AT zhangbaojingzi neuromyelitisopticaspectrumdisorderwithantiaquaporin4antibodyoutcomepredictionmodels AT huangwenjuan neuromyelitisopticaspectrumdisorderwithantiaquaporin4antibodyoutcomepredictionmodels AT changxuechun neuromyelitisopticaspectrumdisorderwithantiaquaporin4antibodyoutcomepredictionmodels AT tanhongmei neuromyelitisopticaspectrumdisorderwithantiaquaporin4antibodyoutcomepredictionmodels AT yujian neuromyelitisopticaspectrumdisorderwithantiaquaporin4antibodyoutcomepredictionmodels AT zhoulei neuromyelitisopticaspectrumdisorderwithantiaquaporin4antibodyoutcomepredictionmodels AT luchuanzhen neuromyelitisopticaspectrumdisorderwithantiaquaporin4antibodyoutcomepredictionmodels AT wangmin neuromyelitisopticaspectrumdisorderwithantiaquaporin4antibodyoutcomepredictionmodels AT dongqiang neuromyelitisopticaspectrumdisorderwithantiaquaporin4antibodyoutcomepredictionmodels AT lujiahong neuromyelitisopticaspectrumdisorderwithantiaquaporin4antibodyoutcomepredictionmodels AT zhaochongbo neuromyelitisopticaspectrumdisorderwithantiaquaporin4antibodyoutcomepredictionmodels AT quanchao neuromyelitisopticaspectrumdisorderwithantiaquaporin4antibodyoutcomepredictionmodels |